Large Scale T-Cell Epitope Discovery

The Large Scale T-Cell Epitope Discovery Master IDIQ, administered by the National Institutes of Health (NIH), establishes a multi-disciplinary contract vehicle focused on advanced immunological research. The primary objective is to support scientific investigations into human T-cell epitopes associated with protection against emerging and re-emerging infectious diseases, with a specific emphasis on potential bioterrorism agents and their associated toxins. This master IDIQ enables NIH to rapidly engage multiple research teams capable of conducting complex, interdisciplinary scientific studies targeting critical infectious disease challenges.

While specific task order details are not provided, the contract vehicle's $10,807,816 shared ceiling suggests significant research investment across multiple prime contractors. These research teams would likely be specialized in immunology, microbiology, and infectious disease disciplines, with probable performance locations including academic research institutions, government laboratories, and advanced medical research facilities. Task orders under this vehicle would typically range from six months to three years, with estimated values likely between $500,000 and $3 million, depending on the complexity and scope of the specific scientific investigation. The contract's focus on emerging infectious diseases and bioterrorism agents indicates potential involvement from agencies like the National Institute of Allergy and Infectious Diseases (NIAID) and potential collaboration with defense and homeland security research programs.